Fatih Özkadı and Barış Alparslan set out the company's case for competitive, lower-carbon value chains and the capital needed to build them. ANTALYA, Türkiye, Nov....
--Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne compared with placebo. --Denifanstat (ASC40)...
First-ever clinical data supporting safety and efficacy of in vivo CAR-T Therapy in refractory systemic lupus erythematosus (SLE) patients. Data shows...